Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess
Roche's idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if another competitor from PureT
Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.